Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease
1 other identifier
observational
42
1 country
1
Brief Summary
The aim of this pilot project is to assess the potential of urine micro-RNAs (miRNA) as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD) compared with patients with other causes of chronic kidney disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
April 26, 2010
CompletedFirst Posted
Study publicly available on registry
May 3, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2012
CompletedNovember 6, 2018
November 1, 2018
2 years
April 26, 2010
November 2, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Identification of micro-RNA Biomarkers Associated with Autosomal Dominant Chronic Kidney Disease
5 years
Study Arms (2)
PKD
Patients with Autosomal Dominant Polycystic Kidney Disease
non-PKD CKD
Patients with non-Polycystic Chronic Kidney Disease
Eligibility Criteria
20 outpatients, 20 patients control
You may qualify if:
- Male or female subject, 18 years of age or older, with diagnosis of ADPKD or non-PKD-CKD
- If female, not pregnant.
- Willing and able to understand and sign informed consent
You may not qualify if:
- Presenting with any signs or symptoms of an infectious disease
- Bacterial infection determined by urine culture
- Use of systemic steroids within a week prior to screening
- History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the Principal Investigator, make the candidate ineligible for the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Rogosin Institutelead
- Rockefeller Universitycollaborator
- Weill Medical College of Cornell Universitycollaborator
Study Sites (1)
The Rogosin Institute
New York, New York, 10021, United States
Biospecimen
Plasma, serum, monocytes, urine
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jon Blumenfeld, MD
The Rogosin Institute
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 26, 2010
First Posted
May 3, 2010
Study Start
April 1, 2010
Primary Completion
April 1, 2012
Study Completion
April 1, 2012
Last Updated
November 6, 2018
Record last verified: 2018-11